ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Phase 1 looking good for Lilly except the usual problem

<< Previous

Bullboard Posts

Next >>

Comment by M101on Mar 31, 2023 5:54pm

161 Views

Post# 35372902

RE:Phase 1 looking good for Lilly except the usual problem

Reminds me of the old door to door salesman who were incapable of hearing the word NO.
But at least you could respect those old liars for their creativity, they weren't all just sociopaths even if they aspired to be (again see Glengarry Glen Ross).
But with these guys, with their multi million dollar lobbyists plus the Fauci factor, the only choice is between sociopath and psychopath.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China